보고서 요약(국문)

개요
전 세계 방사선 독성 치료 시장은 2022년 29억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 6.1%의 성장률을 기록하며 2030년에는 46억 달러에 이를 것으로 예상됩니다. 방사선 독성 치료 시장의 성장은 암 발병률 증가, 고령화 인구 증가, 정부 정책 추진 등의 요인에 의해 주도되고 있습니다. 방사선 독성 치료는 전리 방사선 노출로 인한 건강상의 결과를 다룹니다. 치료 방법은 방사선 노출 정도, 특정 증상, 문제의 심각도에 따라 결정됩니다.
주요 목표는 증상을 관리하고 환자의 전반적인 건강을 유지하는 것입니다. 여기에는 메스꺼움, 구토, 설사와 같은 증상 완화는 물론 통증 관리 및 상처 치료가 포함될 수 있습니다. 치료 효과는 방사선 노출과 치료 시작 시점 사이의 간격에 따라 달라질 수 있습니다. 조기 치료는 일부 부작용을 예방하거나 완화할 수 있습니다.
환자의 치료 옵션은 의료 시설, 전문 치료, 약물 및 의료 인력의 접근성에 따라 결정됩니다. 다양한 조직과 장기에서 방사선 민감도는 각기 다릅니다. 치료 계획은 여러 문제 부위를 표적으로 삼아 특별히 설계됩니다. 방사선 독성 및 관련 치료법에 대한 지속적인 연구를 통해 새로운 치료 접근법과 중재법이 개발될 수 있습니다.
시장 동향
전 세계 암 발병률 증가가 방사선 독성 치료 시장 성장을 견인하고 있습니다.
전 세계적으로 암 발병률이 증가함에 따라 방사선 치료에 대한 수요가 증가하고 있으며, 이는 부작용을 관리하기 위한 효율적인 방사선 독성 치료법에 대한 요구를 뒷받침합니다. 발병률이 변하지 않고 인구 증가 및 고령화가 현재 추세대로 진행된다면 2040년에는 매년 약 2,800만 건의 새로운 암 환자가 발생할 것으로 예상됩니다. 이는 2020년 대비 54.9% 증가한 수치이며, 남성(60.6%)이 여성(48.8%)보다 더 크게 증가할 것으로 예상됩니다.
알코올 섭취, 수면 부족, 흡연, 비만, 고도로 가공된 식품 섭취는 모두 조기 발병 암의 잠재적 위험 요인입니다. 놀랍게도, 연구자들은 성인의 수면 시간이 수년에 걸쳐 크게 변하지 않았음에도 불구하고, 젊은이들의 수면 시간이 수십 년 전보다 훨씬 줄어든다는 사실을 발견했습니다.
고령화 인구 증가로 전 세계 방사선 독성 치료 시장 성장 촉진
인구에서 암은 나이가 들면서 발생할 수 있으며, 암 치료 시 방사선 독성이 나타날 수 있습니다. 연구에 따르면, 노인(65세 이상)은 젊은 사람보다 암 발병 위험이 11배 더 높습니다. 세계 인구 고령화로 인해 향후 20년 동안 노인층의 암 부담은 증가할 것입니다.
나이는 암의 잘 알려진 위험 요소이며, 이는 암 진단 건수 증가로 이어질 수 있습니다. 암 진단과 사망의 대부분은 65세 이상에서 발생합니다. 이러한 공중 보건 문제에 대한 많은 준비가 필요합니다. 노인 암 환자와 생존자의 요구 사항에 대한 포괄적인 접근 방식을 제공하기 위해 이 분야에서 더 많은 연구가 이루어져야 합니다.

방사선 독성 치료의 어려움이 세계 방사선 독성 치료 시장 성장을 저해하고 있습니다.
환자와 의료 전문가 모두 방사선 독성 치료의 이점에 대한 인식이 부족하여 시장 성장이 저해될 수 있습니다. 새로운 방사선 방호 의약품 및 치료법에 대한 규제 승인 절차가 길고 비용이 많이 드는 관계로 혁신적인 제품의 시장 출시가 지연될 수 있습니다. 방사선 독성 치료는 개발 및 마케팅 비용이 많이 들기 때문에 일부 지역이나 특정 의료 시스템 내에서 환자의 접근성이 제한될 수 있습니다.
세분화 분석
세계 방사선 독성 치료 시장은 제품, 적응증, 방사선 유형, 최종 사용자 및 지역별로 세분화됩니다.
급성 방사선 증후군 부문은 예측 기간 동안 시장을 주도할 것으로 예상됩니다.
급성 방사선 증후군 부문은 2022년 방사선 독성 치료 시장에서 약 46.2%의 점유율을 차지하며 가장 높은 시장 점유율을 기록했습니다. 심혈관 질환과 암은 흔히 동반 발생합니다. 항암화학요법, 방사선 치료 및 기타 암 치료는 심혈관계 독성을 유발할 수 있습니다. 관상동맥 질환(CAD), 판막 심장 질환(VHD), 심부전(HF), 심근염, 심근병증, 부정맥, 급성 및 만성 심낭 증후군은 모두 방사선 치료로 인해 발생할 수 있습니다.
방사선 치료로 인한 심장 독성은 다양한 기전에 의해 발생합니다. 방사선 치료 노출과 심장 독성 발생 사이의 간격, 그리고 심장이 노출되는 방사선량 또한 중요한 요인입니다. 심낭 삼출이나 급성 심낭염, 부정맥, 전도 이상과 같은 일부 심장 독성은 방사선 치료 시작 직후에 나타날 수 있지만, 관상동맥 질환, 판막 심장 질환, 만성 심낭 증후군, 심낭 협착과 같은 다른 독성은 수년에 걸쳐 나타날 수 있습니다.

지리적 시장 점유율
북미, 전 세계 방사선 독성 치료 시장에서 지배적인 위치 차지
북미는 2022년 기준 전체 시장 점유율의 약 38.8%를 차지하고 있습니다. 2022년 10월 현재, 암젠(Amgen)의 엔플레이트(Nplate)는 소아 및 성인의 급성 방사선 증후군(ARS) 관련 혈액 세포 손상을 치료하는 데 미국 보건복지부(HHS)가 상당한 금액을 투자할 것으로 예상됩니다. 방사선 질환은 인체가 "단 몇 초 만에 내부 장기에 도달할 수 있는" 고선량의 투과성 방사선에 노출될 때 발생합니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Amgen, Jubilant Pharma Limited, Tanner Pharma Group, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV, Coherus Biosciences Inc. 등이 있습니다.
COVID-19 영향 분석
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁은 지정학적 불안정과 경제적 불확실성으로 인해 시설 부족 현상이 발생하여 방사선 독성 치료 시장에 영향을 미칠 수 있습니다. 분쟁이나 전쟁 중에는 의료 산업, 특히 방사선 독성 치료 분야의 연구 개발 프로젝트에 대한 자원과 관심이 분산될 수 있습니다.
인공지능 분석:
인공지능(AI)은 데이터 분석의 다양한 측면을 개선하기 위해 방사선 독성 치료 시장에서 점점 더 많이 사용되고 있습니다. 방사선영상학(Radiomics)은 의료 영상에서 추출 및 분석된 정량적 특징을 연구하는 학문입니다. 환자의 해부학적 특성을 기반으로 하는 AI 기반 방사선영상분석은 방사선 손상 가능성을 예측할 수 있습니다. 이러한 지식은 의료적 결정을 내리는 데 도움을 주고, 의료진이 독성에 더 취약할 수 있는 환자를 식별하는 데 도움을 줄 수 있습니다.
치료 방법별
• 조영제(CSF)
• 요오드화칼륨
• 프러시안 블루
• 디에틸렌트리아민펜타아세트산(DTPA)
• 기타
적응증별
• 급성 방사선 증후군
o 골수 증후군
o 위장관 증후군
o 심혈관 증후군
• 만성 방사선 증후군
방사선 종류별
• 이온화 방사선
o 알파 방사선
o 베타 방사선
o 감마 방사선
• 비전이온화 방사선
최종 사용자별
• 병원
• 전문 클리닉
• 기타
• 지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2023년 3월, 코헤러스 바이오사이언스(Coherus BioSciences, Inc.)는 미국 식품의약국(FDA)이 발열성 호중구 감소증으로 나타나는 감염 가능성을 줄이기 위해 항암화학요법 다음 날 투여하는 바이오시밀러 페그필그라스팀인 UDENYCA(pegfilgrastim-cbqv)를 승인했다고 발표했습니다. UDENYCA 자동주사기는 사용이 간편하고 직관적인 디자인으로 병원 및 가정 환경 모두에서 사용하기에 적합합니다. 이 약은 골수 억제성 방사선 치료를 받는 환자(급성 방사선 증후군의 조혈계 아증후군)의 생존 가능성을 높이는 데 사용됩니다.
보고서 구매 이유

• 제품, 적응증, 방사선 유형, 최종 사용자 및 지역별 글로벌 방사선 독성 치료 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위해

• 모든 부문을 포함한 방사선 독성 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료.

글로벌 방사선 독성 치료 시장 보고서는 약 69개의 표, 69개의 그림, 그리고 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The Global Radiation Toxicity Treatment Market reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.6 billion by 2030 growing with a CAGR of 6.1% during the forecast period 2023-2030. The radiation toxicity treatment market is driven by factors such as increasing cancer incidence, rising aging population and government initiatives. The health consequences of exposure to ionizing radiation constitutes radiation toxicity treatment. The method of treatment is determined by the degree of radiation exposure, the particular symptoms, and the seriousness of the problem.
Managing symptoms and preserving the patient's general health are the major priorities. This may involve dealing with concerns including nausea, vomiting, and diarrhea as well as managing pain and taking care of open wounds.The efficiency of interventions can be impacted by the interval between radiation exposure and the start of therapy. Early intervention may stop or lessen some effects.
The treatment options of a patient will be dependent on the accessibility of medical facilities, specialist therapies, drugs, and healthcare personnel. Radiation sensitivity varies among various tissues and organs. Treatment plans will be specifically designed to target the many problematic areas. New therapeutic approaches and interventions may be developed as a result of ongoing study on radiation toxicity and related therapies.
Market Dynamics
The Increasing Cancer Incidence are Driving the Global Radiation Toxicity Treatment Market Growth
The need for radiation therapy is driven by the rising incidence of cancer worldwide, which in turn supports the desire for efficient radiation toxicity treatments to manage the side effects. If incidence stays unchanged and population growth and aging follow current trends, there will be an estimated 28 million new cancer cases annually by 2040. This represents an increase of 54.9% from 2020, and it is anticipated that males will have a greater increase (60.6%) than girls (48.8%).
Alcohol intake, sleep deprivation, smoking, obesity, and consuming highly processed foods were all potential risk factors for early-onset cancer. Surprisingly, researchers discovered that youngsters are getting far less sleep now than they did decades ago, despite the fact that adult sleep length hasn't changed significantly over the years.
The Increasing Aging Population Boost The Global Radiation Toxicity Treatment Market Growth
In population cancer may develop with age and its treatment radiation toxicity comes. According to research, older adults (defined as those 65 and older) had an 11 times higher risk of developing cancer than younger people. The burden of cancer among the elderly will increase during the next 20 years due to the aging of the world population.
Age is a well-known risk factor for cancer, which could lead to an increase in the number of cancer diagnoses. The bulk of cancer diagnoses and cancer deaths occur in people over 65. A lot of preparation is required for this expanding public health concern. To provide a thorough approach to the requirements of elderly cancer patients and survivors, more work must be done in this area.
Challenges with Radiation Toxicity Treatment are Hampering the Global Radiation Toxicity Treatment Market Growth
Growth of the market may be hampered by a lack of knowledge about the advantages of radiation toxicity therapies among patients and medical professionals. The introduction of innovative items to the market may be slowed back by the lengthy and expensive regulatory approvals process for new radioprotective medications and treatments. Radiation toxicity treatments may be expensive to develop and market, which may limit patient access in some areas or within particular healthcare systems.
Segment Analysis
The global radiation toxicity treatment market is segmented based on product, indication, radiation type, end-user and region.
The Acute Radiation Syndrome Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period
The acute radiation syndrome segment accounted for the highest market stake accounting for approximately 46.2% of the radiation toxicity treatment market in 2022. Cardiovascular illness and cancer frequently co-occur. Cardiovascular toxicities can be caused by chemotherapy, radiation therapy, and other cancer treatments. Coronary artery disease (CAD), valvular heart disease (VHD), heart failure (HF), myocarditis, cardiomyopathies, arrhythmias, and acute and chronic pericardial syndromes may all be brought on by radiation treatment.
Cardiotoxicities brought on by radiation therapy are caused by a variety of processes. The interval between radiation therapy exposure and the onset of cardiac toxicities, as well as the radiation dose to which the heart is exposed, are additional crucial factors. While some cardiac toxicities, such as pericardial effusion or acute pericarditis, arrhythmic events, and conduction abnormalities, can manifest right away after the start of radiotherapies, others, like coronary artery disease, valvular heart disease, chronic pericardial syndromes, and constriction, can take years to manifest.
Geographical Penetration
North America Holds a Dominant Position in the Global Radiation Toxicity Treatment Market
North America is holding around 38.8% of the total market share in 2022. As of October 2022, the acute radiation syndrome (ARS)-related blood cell damage that Nplate from Amgen treats in both children and adults will cost the U.S. Department of Health and Human Services (HHS) an undisclosed amount of money to lock up. When a person's body is subjected to a high dose of penetrating radiation, which is capable of "reaching internal organs in a matter of seconds,", is also known as radiation sickness.
Competitive Landscape
The major global players in the market include Amgen, Jubilant Pharma Limited, Tanner Pharma Group, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV, and Coherus Biosciences Inc. among others.
COVID-19 Impact Analysis
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war may affect the radiation toxicity treatment market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Resources and attention may be diverted away from research and development projects in the healthcare industry, particularly radiation toxicity therapy, during times of conflict or war.
Artificial Intelligence Analysis:
Artificial intelligence (AI) is increasingly being used in the radiation toxicity treatment market to improve various aspects of data analysis. Radiomics is the study of quantitative features extracted and analyzed from medical pictures. Based on the particular characteristics of a patient's anatomy, AI-driven radiomics may forecast the likelihood of radiation damage. This knowledge can direct medical decisions and assist practitioners in identifying patients who could be more vulnerable to toxicity.
By Treatment
• Colony Stimulating Factors
• Potassium Iodide
• Prussian Blue
• Diethylenetriamine Pentaacetic Acid
• Others
By Indication
• Acute Radiation Syndrome
o Bone Marrow Syndrome
o Gastrointestinal Syndrome
o Cardiovascular syndrome
• Chronic Radiation Syndrome
By Radiation Type
• Ionizing Radiation
o Alpha Radiation
o Beta Radiation
o Gamma Radiation
• Non-ionizing Radiation
By End-user
• Hospitals
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In March 2023, Coherus BioSciences, Inc. reported that The U.S. Food and Drug Administration approved UDENYCA (pegfilgrastim-cbqv), a biosimilar pegfilgrastim that is given the day after chemotherapy to lessen the likelihood of infection as seen by febrile neutropenia. The UDENYCA autoinjector has a simple, user-friendly design that makes it suitable for usage in both in-office and at-home care settings. It is indicated to patients who receive radiation doses that are myelosuppressive in nature are more likely to survive (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
Why Purchase the Report?
• To visualize the global radiation toxicity treatment market segmentation based on the product, indication, radiation type, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of radiation toxicity treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of critical products of all the major players.
The global radiation toxicity treatment market report would provide approximately 69 tables, 69 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Indication
3.3. Snippet by Radiation Type
3.4. Snippet by End-user
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising cancer incidence
4.1.2. Restraints
4.1.2.1. Challenges associated with radiation toxicity treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Product
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.1.2. Market Attractiveness Index, By Product
9.2. Colony Stimulating Factors*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Potassium Iodide
9.4. Prussian Blue
9.5. Diethylenetriamine Pentaacetic Acid
9.6. Others
10. By Indication
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.1.2. Market Attractiveness Index, By Indication
10.2. Acute Radiation Syndrome*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Bone Marrow Syndrome
10.2.4. Gastrointestinal Syndrome
10.2.5. Cardiovascular syndrome
10.3. Chronic Radiation Syndrome
11. By Radiation Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
11.1.2. Market Attractiveness Index, By Radiation Type
11.1.3. Ionizing Radiation*
11.1.4. Introduction
11.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.1.5.1. Alpha Radiation
11.1.5.2. Beta Radiation
11.1.5.3. Gamma Radiation
11.1.6. Non-ionizing Radiation
12. By End-user
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.1.2. Market Attractiveness Index, By End-user
12.1.3. Hospitals*
12.1.3.1. Introduction
12.1.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.1.4. Specialty Clinics
12.1.5. Others
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14. Competitive Landscape
14.1. Competitive Scenario
14.2. ProductBenchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. Company Profiles
15.1. Amgen*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Jubilant Pharma Limited
15.3. Tanner Pharma Group
15.4. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
15.5. Recipharm AB
15.6. Mission Pharmacal Company
15.7. Partner Therapeutics, Inc.
15.8. Novartis AG
15.9. Mylan NV
15.10. Coherus Biosciences Inc.
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Amgen, 4.	Key Developments, Jubilant Pharma Limited, Tanner Pharma Group, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV, Coherus Biosciences Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Radiation Toxicity Treatment Market Value, By Product, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Radiation Toxicity Treatment Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Radiation Toxicity Treatment Market Value, By Radiation Type, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Radiation Toxicity Treatment Market Value, By End-user, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Radiation Toxicity Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Radiation Toxicity Treatment Market Value, By Product, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Radiation Toxicity Treatment Market Value, By Product, 2021-2030 (US$ Million)

Table 8 Global Radiation Toxicity Treatment Market Value, By Indication, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Radiation Toxicity Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 10 Global Radiation Toxicity Treatment Market Value, By Radiation Type, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Radiation Toxicity Treatment Market Value, By Radiation Type, 2021-2030 (US$ Million)

Table 12 Global Radiation Toxicity Treatment Market Value, By End-user, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Radiation Toxicity Treatment Market Value, By End-user, 2021-2030 (US$ Million)

Table 14 Global Radiation Toxicity Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Radiation Toxicity Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Radiation Toxicity Treatment Market Value, By Product, 2021-2030 (US$ Million)

Table 17 North America Radiation Toxicity Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 18 North America Radiation Toxicity Treatment Market Value, By Radiation Type, 2021-2030 (US$ Million)

Table 19 North America Radiation Toxicity Treatment Market Value, By End-user, 2021-2030 (US$ Million)

Table 20 North America Radiation Toxicity Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Radiation Toxicity Treatment Market Value, By Product, 2021-2030 (US$ Million)

Table 22 South America Radiation Toxicity Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 23 South America Radiation Toxicity Treatment Market Value, By Radiation Type, 2021-2030 (US$ Million)

Table 24 South America Radiation Toxicity Treatment Market Value, By End-user, 2021-2030 (US$ Million)

Table 25 South America Radiation Toxicity Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Radiation Toxicity Treatment Market Value, By Product, 2021-2030 (US$ Million)

Table 27 Europe Radiation Toxicity Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 28 Europe Radiation Toxicity Treatment Market Value, By Radiation Type, 2021-2030 (US$ Million)

Table 29 Europe Radiation Toxicity Treatment Market Value, By End-user, 2021-2030 (US$ Million)

Table 30 Europe Radiation Toxicity Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Radiation Toxicity Treatment Market Value, By Product, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Radiation Toxicity Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Radiation Toxicity Treatment Market Value, By Radiation Type, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Radiation Toxicity Treatment Market Value, By End-user, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Radiation Toxicity Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Radiation Toxicity Treatment Market Value, By Product, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Radiation Toxicity Treatment Market Value, By Indication, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Radiation Toxicity Treatment Market Value, By Radiation Type, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Radiation Toxicity Treatment Market Value, By End-user, 2021-2030 (US$ Million)

Table 40 Amgen: Overview

Table 41 Amgen: ProductPortfolio

Table 42 Amgen: Key Developments

Table 43 Jubilant Pharma Limited: Overview

Table 44 Jubilant Pharma Limited: ProductPortfolio

Table 45 Jubilant Pharma Limited: Key Developments

Table 46 Tanner Pharma Group: Overview

Table 47 Tanner Pharma Group: ProductPortfolio

Table 48 Tanner Pharma Group: Key Developments

Table 49 Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG: Overview

Table 50 Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG: ProductPortfolio

Table 51 Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG: Key Developments

Table 52 Recipharm AB: Overview

Table 53 Recipharm AB: ProductPortfolio

Table 54 Recipharm AB: Key Developments

Table 55 Mission Pharmacal Company: Overview

Table 56 Mission Pharmacal Company: ProductPortfolio

Table 57 Mission Pharmacal Company: Key Developments

Table 58 Partner Therapeutics, Inc.: Overview

Table 59 Partner Therapeutics, Inc.: ProductPortfolio

Table 60 Partner Therapeutics, Inc.: Key Developments

Table 61 Novartis AG: Overview

Table 62 Novartis AG: ProductPortfolio

Table 63 Novartis AG: Key Developments

Table 64 Mylan NV: Overview

Table 65 Mylan NV: ProductPortfolio

Table 66 Mylan NV: Key Developments

Table 67 Coherus Biosciences Inc.: Overview

Table 68 Coherus Biosciences Inc.: ProductPortfolio

Table 69 Coherus Biosciences Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Radiation Toxicity Treatment Market Share, By Product, 2022 & 2030 (%)

Figure 3 Global Radiation Toxicity Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 4 Global Radiation Toxicity Treatment Market Share, By Radiation Type, 2022 & 2030 (%)

Figure 5 Global Radiation Toxicity Treatment Market Share, By End-user, 2022 & 2030 (%)

Figure 6 Global Radiation Toxicity Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Radiation Toxicity Treatment Market Y-o-Y Growth, By Product, 2022-2030 (%)

Figure 8 Colony Stimulating Factors Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Potassium Iodide Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Prussian Blue Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Elastics Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Diethylenetriamine Pentaacetic Acid Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Others Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Global Radiation Toxicity Treatment Market Y-o-Y Growth, By Indication, 2022-2030 (%)

Figure 15 Acute Radiation Syndrome Indication in Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Chronic Radiation Syndrome Indication in Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Global Radiation Toxicity Treatment Market Y-o-Y Growth, By Radiation Type, 2022-2030 (%)

Figure 18 Ionizing Radiation Radiation Type in Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Non-ionizing Radiation Radiation Type in Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Radiation Toxicity Treatment Market Y-o-Y Growth, By End-user, 2022-2030 (%)

Figure 21 Hospitals End-user in Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Specialty Clinics End-user in Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Others End-user in Global Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Global Radiation Toxicity Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Asia-Pacific Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Europe Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 South America Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 Middle East and Africa Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 North America Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 31 North America Radiation Toxicity Treatment Market Share, By Product, 2022 & 2030 (%)

Figure 32 North America Radiation Toxicity Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 33 North America Radiation Toxicity Treatment Market Share, By Radiation Type, 2022 & 2030 (%)

Figure 34 North America Radiation Toxicity Treatment Market Share, By End-user, 2022 & 2030 (%)

Figure 35 North America Radiation Toxicity Treatment Market Share, By 0, 2022 & 2030 (%)

Figure 36 North America Radiation Toxicity Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 37 South America Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 38 South America Radiation Toxicity Treatment Market Share, By Product, 2022 & 2030 (%)

Figure 39 South America Radiation Toxicity Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 40 South America Radiation Toxicity Treatment Market Share, By Radiation Type, 2022 & 2030 (%)

Figure 41 South America Radiation Toxicity Treatment Market Share, By End-user, 2022 & 2030 (%)

Figure 42 South America Radiation Toxicity Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 43 Europe Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 44 Europe Radiation Toxicity Treatment Market Share, By Product, 2022 & 2030 (%)

Figure 45 Europe Radiation Toxicity Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 46 Europe Radiation Toxicity Treatment Market Share, By Radiation Type, 2022 & 2030 (%)

Figure 47 Europe Radiation Toxicity Treatment Market Share, By End-user, 2022 & 2030 (%)

Figure 48 Europe Radiation Toxicity Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 49 Asia-Pacific Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 50 Asia-Pacific Radiation Toxicity Treatment Market Share, By Product, 2022 & 2030 (%)

Figure 51 Asia-Pacific Radiation Toxicity Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 52 Asia-Pacific Radiation Toxicity Treatment Market Share, By Radiation Type, 2022 & 2030 (%)

Figure 53 Asia-Pacific Radiation Toxicity Treatment Market Share, By End-user, 2022 & 2030 (%)

Figure 54 Asia-Pacific Radiation Toxicity Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 55 Middle East & Africa Radiation Toxicity Treatment Market Value, 2021-2030 (US$ Million)

Figure 56 Middle East & Africa Radiation Toxicity Treatment Market Share, By Product, 2022 & 2030 (%)

Figure 57 Middle East & Africa Radiation Toxicity Treatment Market Share, By Indication, 2022 & 2030 (%)

Figure 58 Middle East & Africa Radiation Toxicity Treatment Market Share, By Radiation Type, 2022 & 2030 (%)

Figure 59 Middle East & Africa Radiation Toxicity Treatment Market Share, By End-user, 2022 & 2030 (%)

Figure 60 Amgen: Financials

Figure 61 Jubilant Pharma Limited: Financials

Figure 62 Tanner Pharma Group: Financials

Figure 63 Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG: Financials

Figure 64 Recipharm AB: Financials

Figure 65 Mission Pharmacal Company: Financials

Figure 66 Partner Therapeutics, Inc.: Financials

Figure 67 Novartis AG: Financials

Figure 68 Mylan NV: Financials

Figure 69 Coherus Biosciences Inc.: Financials

세계 방사선 독성 치료 시장 – 2023-2030

Global Radiation Toxicity Treatment Market - 2023-2030